Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Dev Orig Health Dis ; 14(2): 261-271, 2023 04.
Article in English | MEDLINE | ID: mdl-36189641

ABSTRACT

Maternal obesity and malnutrition during gestation and lactation have been recognized to increase the risk of obesity and metabolic disorders in the offspring across their lifespan. However, the gestational period during which malnutrition exerts a decisive effect is unclear. Brown adipose tissue (BAT) plays a critical role in energy metabolism owing to its high efficiency in oxidizing glucose and fatty acids. This study aimed to determine the impact of maternal high-fat diet (HFD) consumption only during pregnancy on BAT and energy metabolism in offspring mice. Dams were fed an HFD or a normal chow diet from embryonic day 2.5. HFD consumption during pregnancy induced glucose intolerance and hypertension in dams. In the offspring of HFD-fed dams, maternal HFD lowered fetal weight without affecting placental weight, whereas HFD consumption after birth exacerbated oxygen consumption and cold-induced thermogenesis at 12 months of age, accompanied by increased lipid droplet size in BAT. These data demonstrate that HFD consumption only during pregnancy exerts a long-lasting effect on BAT. Collectively, these findings indicate the importance of nutrition during pregnancy with respect to the energy metabolism of the offspring, and pregnant women should thus ensure proper nutrition during pregnancy to ensure normal energy metabolism in the offspring.


Subject(s)
Adipose Tissue, Brown , Malnutrition , Female , Humans , Pregnancy , Animals , Mice , Diet, High-Fat/adverse effects , Fetal Weight , Placenta
2.
Cancer Med ; 10(18): 6442-6455, 2021 09.
Article in English | MEDLINE | ID: mdl-34472721

ABSTRACT

Rhabdomyosarcoma exhibits tumor-specific energy metabolic changes that include the Warburg effect. Since targeting cancer metabolism is a promising therapeutic approach, we examined the antitumor effects of suppressing lipid metabolism in rhabdomyosarcoma. We suppressed lipid metabolism in rhabdomyosarcoma cells in vitro by administering an inhibitor of malonyl-CoA decarboxylase, which increases malonyl-CoA and decreases fatty acid oxidation. Suppression of lipid metabolism in rhabdomyosarcoma cells decreased cell proliferation by inducing cell cycle arrest. Metabolomic analysis showed an increase in glycolysis and inactivation of the pentose phosphate pathway. Immunoblotting analysis revealed upregulated expression of the autophagy marker LC3A/B-II due to increased phosphorylation of AMP-activated protein kinase, a nutrient sensor. p21 protein expression level also increased. Inhibition of both lipid metabolism and autophagy suppressed tumor proliferation and increased apoptosis. In vivo studies involved injection of human Rh30 cells into the gastrocnemius muscle of 6-week-old female nude mice, which were divided into normal chow and low-fat diet groups. The mice fed a low-fat diet for 21 days showed reduced tumor growth compared to normal chow diet-fed mice. Suppression of lipid metabolism disrupted the equilibrium of the cancer-specific metabolism in rhabdomyosarcoma, resulting in a tumor growth-inhibition effect. Therefore, the development of treatments focusing on the lipid dependence of rhabdomyosarcoma is highly promising.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboxy-Lyases/antagonists & inhibitors , Diet, Fat-Restricted , Lipid Metabolism/drug effects , Rhabdomyosarcoma/drug therapy , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , Autophagy/drug effects , Carboxy-Lyases/metabolism , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Combined Modality Therapy/methods , Fatty Acids/metabolism , Female , Humans , Macrolides/pharmacology , Macrolides/therapeutic use , Malonyl Coenzyme A/metabolism , Mice , Muscle, Skeletal/pathology , Oxidation-Reduction/drug effects , Phenylurea Compounds/pharmacology , Phenylurea Compounds/therapeutic use , Rhabdomyosarcoma/pathology , Rhabdomyosarcoma/therapy , Xenograft Model Antitumor Assays
3.
PLoS One ; 16(3): e0247886, 2021.
Article in English | MEDLINE | ID: mdl-33684119

ABSTRACT

OBJECTIVES: To investigate the growth velocity-improving effects of vitamin D replacement therapy in pediatric patients diagnosed with vitamin D deficiency and insufficiency. STUDY DESIGN: A retrospective cohort study was conducted in 34 pediatric patients diagnosed with vitamin D deficiency/insufficiency. Based on the clinical findings, the subjects were divided into two groups: a bowed leg (BL) group and a non-bowed leg (non-BL) group. After the initiation of alfacalcidol, the standard deviation score (SDS) of their heights, weights and growth velocities in each group were monitored. RESULTS: The median age at the first visit was significantly lesser in the BL group (1.58 years old [interquartile range (IQR): 1.33, 2.17]) than that in the non-BL group (3.00 years old [IQR: 2.33, 3.67]). On the contrary, the SDS for height was significantly lower in the non-BL group (-2.27 [IQR: -2.63, -1.94]) than that in the BL group (-1.37 [IQR: -1.91, -1.07]). One-year treatment with alfacalcidol showed significant improvements in both height SDSs and growth velocity SDSs not only in the BL group but also in the non-BL group. CONCLUSIONS: The current study revealed that vitamin D replacement therapy improved the growth rate in children with vitamin D deficiency/insufficiency, regardless of the presence of BL. This study emphasizes the importance of assessing the vitamin D status in children with poor growth rates and suggests that alfacalcidol could be a valid option for the treatment of short stature.


Subject(s)
Child Development/drug effects , Hydroxycholecalciferols/administration & dosage , Vitamin D Deficiency/drug therapy , Child, Preschool , Female , Humans , Infant , Male , Retrospective Studies , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/physiopathology
4.
Clin Pediatr Endocrinol ; 29(4): 189-193, 2020.
Article in English | MEDLINE | ID: mdl-33088019

ABSTRACT

We report a case of 15-yr-old phenotypically normal male with short stature associated with the chromosomal abnormalities of 46,X,psu idic(Y)(q11.2)/45,X. At 3 yr of age, he underwent urethroplasty for scrotal hypospadias. At 15 yr of age, he was referred to our hospital due to short stature (-3.71 SD). The results of blood examination were mostly normal. A radiological examination revealed his bone age was 15.7 yr (based on the TW2-RUS method). Chromosome analysis of peripheral lymphocytes revealed 46,X,psu idic(Y)(q11.2)[16]/45,X[14], and array comparative genomic hybridization (aCGH) showed a large deletion of Yq which was located distal to the Y chromosome growth-control gene (GCY) region. It is likely that these structural abnormalities in the Y chromosome were responsible for the short stature. This case might provide new insights regarding GCY and emphasizes the importance of chromosome analysis in not only females but also males with short stature, especially when associated with genital anomalies.

5.
Am J Physiol Endocrinol Metab ; 317(6): E1140-E1149, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31638856

ABSTRACT

The angiotensin II (ANG II)-ANG II type 1 receptor (AT1R) axis is a key player in the pathophysiology of obesity. Angiotensin-converting enzyme 2 (ACE2) counteracts the ANG II/AT1R axis via converting ANG II to angiotensin 1-7 (Ang 1-7), which is known to have an anti-obesity effect. In this study, we hypothesized that ACE2 exerts a strong anti-obesity effect by increasing Ang 1-7 levels. We injected intraperitoneally recombinant human ACE2 (rhACE2, 2.0 mg·kg-1·day-1) for 28 days to high-fat diet (HFD)-induced obesity mice. rhACE2 treatment decreased body weight and improved glucose metabolism. Furthermore, rhACE2 increased oxygen consumption and upregulated thermogenesis in HFD-fed mice. In the rhACE2 treatment group, brown adipose tissue (BAT) mass increased, accompanied with ameliorated insulin signaling and increased protein levels of uncoupling protein-1 (UCP-1) and PRD1-BF1-RIZ1 homologous domain containing 16. Importantly, subcutaneous white adipose tissue (sWAT) mass decreased, concomitant with browning, which was established by the increase of UCP-1 expression. The browning is the result of increased H3K27 acetylation via the downregulation of histone deacetylase 3 and increased H3K9 acetylation via upregulation of GCN5 and P300/CBP-associated factor. These results suggest that rhACE2 exerts anti-obesity effects by stimulating BAT and inducing browning in sWAT. ACE2 and the Ang 1-7 axis represent a potential therapeutic approach to prevent the development of obesity.


Subject(s)
Adipose Tissue, Brown/drug effects , Adipose Tissue, White/drug effects , Angiotensin I/drug effects , Body Weight/drug effects , Obesity/metabolism , Peptide Fragments/drug effects , Peptidyl-Dipeptidase A/pharmacology , Thermogenesis/drug effects , Acetylation/drug effects , Adipose Tissue, Brown/metabolism , Adipose Tissue, White/metabolism , Angiotensin I/metabolism , Angiotensin-Converting Enzyme 2 , Animals , Diet, High-Fat , Down-Regulation , Histone Code/drug effects , Histone Deacetylases/drug effects , Histone Deacetylases/metabolism , Humans , Insulin/metabolism , Male , Mice , Mice, Inbred C57BL , Peptide Fragments/metabolism , Recombinant Proteins , Subcutaneous Fat/drug effects , Subcutaneous Fat/metabolism , Uncoupling Protein 1/drug effects , Uncoupling Protein 1/metabolism , p300-CBP Transcription Factors/drug effects , p300-CBP Transcription Factors/metabolism
6.
Jpn J Infect Dis ; 70(1): 105-107, 2017 Jan 24.
Article in English | MEDLINE | ID: mdl-27000454

ABSTRACT

Saffold cardiovirus (SAFV), first identified in a stool sample in 2007, is thought to be associated with respiratory disease and gastroenteritis. On the other hand, animal experiments suggested that the major viral load, following intraperitoneal inoculation of SAFV in mice, may be detected in the pancreas. However, until now, no cases of SAFV in patients with pancreatitis have been reported. This report presents a unique case in a patient who developed relapsing acute pancreatitis (AP) after hand, foot, and mouth disease, and was suspected to have SAFV-1 infection. A 2-year-old boy was admitted to the hospital because of severe abdominal pain. His serum amylase and lipase levels were elevated. Enhanced computed tomography showed pancreatic swelling and dilation of the main pancreatic duct, leading to a diagnosis of severe AP. The viral genome of SAFV-1 was detected by reverse transcription polymerase chain reaction from fecal samples. Furthermore, the serum neutralization titer for SAFV was elevated during AP, but decreased after 1 year. These findings strongly suggest the patient developed SAFV-1 infection concurrent with AP. Therefore, we propose that a cohort study is required to clarify the relationship between SAFV and AP.


Subject(s)
Cardiovirus Infections/diagnosis , Cardiovirus Infections/pathology , Cardiovirus/isolation & purification , Pancreatitis, Acute Necrotizing/diagnosis , Pancreatitis, Acute Necrotizing/pathology , Amylases/blood , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Child, Preschool , Feces/virology , Hand, Foot and Mouth Disease/complications , Humans , Lipase/blood , Male , Pancreas/diagnostic imaging , Pancreas/pathology , RNA, Viral/genetics , RNA, Viral/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction , Tomography, X-Ray Computed
7.
Pediatr Int ; 57(4): 791-4, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25847601

ABSTRACT

Relapsed anaplastic large cell lymphoma (ALCL) is chemosensitive, but recurrence is common. Although vinblastine (VLB) monotherapy is an effective treatment for relapsed ALCL, the optimal treatment duration is unknown, and some patients experience further relapse after completing the treatment. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is also an effective treatment for relapsed ALCL, although transplant-related toxicity is a problem. Here, we report an 11-year-old patient with relapsed ALCL who underwent induction therapy with VLB monotherapy and achieved complete remission (CR) after 12 courses. CR was confirmed on positron emission tomography-computed tomography. The patient then underwent allo-HSCT with reduced intensity conditioning (fludarabine, melphalan, and low-dose total body irradiation). He developed grade II acute graft-versus-host disease (GVHD), which was successfully treated with methylprednisolone. There was no evidence of chronic GVHD. He has remained in CR without any complications for 19 months after allo-HSCT.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Hematopoietic Stem Cell Transplantation , Lymphoma, Large-Cell, Anaplastic/drug therapy , Vinblastine/therapeutic use , Behavior Therapy , Child , Graft vs Host Disease , Humans , Lymphoma, Large-Cell, Anaplastic/therapy , Male , Remission Induction , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL